This page contains a Flash digital edition of a book.
Genomics


samples also can be handled cost-efficiently with- out the need for indexing or bar-coding, which means processing can occur at any time, and in any order, without delay or concerns about potential regulatory issues. QIAGEN is convinced that NGS is making a transformational impact on life sci- ence, but challenges are limiting more widespread adoption for clinical purposes. The development of the company’s complete sample-to-result workflow is a key achievement in its initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content and services. QIAGEN is planning to begin placing NGS workflows with selected customer groups during 2013 and expects NGS to complement established molecular technologies, particularly real-time PCR. The adoption of NGS in clinical research and diagnostics has been hampered for various reasons, particularly workflow challenges that become more pronounced in clinical settings due to the increased number of samples being processed. Other challenges include manual sam- ple preparation, delays caused by batching samples


Sample & Assay Technologies


Offering a seamless sample-to-result NGS workflow NGS workflow


Primary sample to purified


DNA / RNA


Leading innovative FFPE sample preparation


Gene panels with built-in QC


Extreme


efficiency and least bias


Random access Scalable


Cost-effective


DNA / RNA preprocessing


Target


Sample & Assay Technologies Library


enrichment preparation Data NGS run


alignment / analysis


Automated data processing


Select customer group


placements planned for 2013: QIAcube NGS / GeneReader


AGBT Meeting, Marco Island, February 2013 7


Figure 19: Complete and automated NGS workflow solution from QIAGEN, addressing clinical research and diagnostic settings


Uncoverc relevant


biomarkers.


Monitor healthy populations.


1000 100 10 1


0.1 0.01 Healthy Disease


Healthy subjects are not always detectable with traditional ELISAs, whereas Singulex immunoassays can quantify both healthy and disease cohorts.


ELISA LLoQ Singulex LLoQ


Imagine what you can accomplish by quantifying previously undetectable biomarkers.


Uncover clinically relevant biomarkers faster and with more confidence. Powered by Singulex digital technology, you can measure low-abundance biomarkers accurately and reliably, even in healthy individuals.


Want to see the data? It’s waiting for you at www.singulex.com/imagine


Drug Discovery World Spring 2013


37


Biomarker Concentration in pg/mL


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80